News | Contrast Media | August 17, 2023

Researchers Discover Contrast Dye Shortage Affected Assessment of Stroke Patients

Study investigated impact of radiographic media contrast shortage on stroke patient scan data 

Study investigated impact of radiographic media contrast shortage on stroke patient scan data

A study investigated impact of radiographic media contrast shortage on stroke patient scan data. Getty Images 


August 17, 2023 — University of Missouri School of Medicine neurologist Adnan Qureshi, MD recently led a study that discovered last year’s iodinated media contrast dye shortage affected the assessment of stroke patients at hospitals across the country. Injecting or drinking the media contrast helps doctors see blood vessels and organs more clearly in an x-ray or a computed tomography (CT) scan. 

Two specialized CT scans, CT angiographs (CTA) and CT perfusion (CTP) use the dye to check blood flow and the health of blood vessels. According to the study, the number of CTA and CTP scans across the country decreased during the shortage, which lasted from mid-April to early June of 2022. CTA scans decreased by around 10%, and CTP scans decreased by 26%. 

“The reduction was smaller than expected because there are other manufacturers of contrast media in the United States,” Qureshi said. “The reduction in CTPs was much greater and can be explained by how neurointerventionalists and stroke physicians use these tests. A CTA is important to identify if there is any blockage in the brain blood vessels that can be treated by clot removal. CTPs help identify whether there is salvageable brain tissue.” 

The shortage occurred after a COVID-19 outbreak forced a General Electric production facility in Shanghai, China to lockdown. As a result, GE Healthcare announced they would ration orders of the dye to medical facilities. While there were other suppliers worldwide, none could compensate for the drop in supply. 

Qureshi said these findings highlight the need to reduce the reliance on radiographic media contrast imaging without compromising patient outcomes. Some suggested methods include doing more magnetic resonance imaging (MRI) scans and reducing the amount of dye used per patient. 

“Another aspect that needs to be considered is whether comprehensive stroke centers should be prioritized during a contrast media shortage, since they are seeing a larger number of stroke patients and are also selecting patients for clot removal treatments,” Qureshi said. 

The research team analyzed data of more than 70,000 patients associated with Viz.ai, a commercial neuroimaging database. The data was anonymized and compliant with HIPAA guidelines and did not compromise any patient health information. 

Effect of Radiographic Contrast Media Shortage on Stroke Evaluation in the United States was published July 2023 in the American Journal of Neuroradiology

For more information: https://missouri.edu/ 


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now